UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

Hepatology (Baltimore, Md.), 2010-09, Vol.52 (3), p.886-893

2010

Volltextzugriff (PDF)

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

Hepatology (Baltimore, Md.), 2010-02, Vol.51 (2), p.422-430

2010

Volltextzugriff (PDF)

Agalactosyl IgG induces liver fibrogenesis via Fc gamma receptor 3a on human hepatic stellate cells

The Journal of pathology, 2024-08, Vol.263 (4-5), p.508-519

2024

Volltextzugriff (PDF)

Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B

Hepatology (Baltimore, Md.), 2008-09, Vol.48 (3), p.750-758

2008

Volltextzugriff (PDF)

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

Gastroenterology (New York, N.Y. 1943), 2006-12, Vol.131 (6), p.1743-1751

2006

Volltextzugriff (PDF)

Urine DNA biomarkers for hepatocellular carcinoma screening

British journal of cancer, 2022-06, Vol.126 (10), p.1432-1438

2022

Volltextzugriff (PDF)

Vortex Ring Formation Following Shock Wave Diffraction in Low-Pressure Environments

Flow, turbulence and combustion, 2023-11, Vol.111 (4), p.1127-1138

2023

Volltextzugriff (PDF)

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

Hepatology (Baltimore, Md.), 2011-01, Vol.53 (1), p.62-72

2011

Volltextzugriff (PDF)

Drug‐induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan

Liver international, 2021-11, Vol.41 (11), p.2671-2680

2021

Volltextzugriff (PDF)

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

The New England journal of medicine, 2006-03, Vol.354 (10), p.1001-1010

2006

Volltextzugriff (PDF)

Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

Gastroenterology (New York, N.Y. 1943), 2007-11, Vol.133 (5), p.1437-1444

2007

Volltextzugriff (PDF)

Novel urine cell-free DNA methylation markers for hepatocellular carcinoma

Scientific reports, 2023-12, Vol.13 (1), p.21585-21585, Article 21585

2023

Volltextzugriff (PDF)

Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations

Journal of biomedical science, 2018-06, Vol.25 (1), p.51-12, Article 51

2018

Volltextzugriff (PDF)

Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program

Hepatology (Baltimore, Md.), 2015-06, Vol.61 (6), p.1870-1879

2015

Volltextzugriff (PDF)

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis

Cancer Immunology, Immunotherapy, 2021-07, Vol.70 (7), p.1929-1937

2021

Volltextzugriff (PDF)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV

BMC infectious diseases, 2022-04, Vol.22 (1), p.351-9, Article 351

2022

Volltextzugriff (PDF)

All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study

Liver international, 2016-10, Vol.36 (10), p.1433-1441

2016

Volltextzugriff (PDF)

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Gastroenterology (New York, N.Y. 1943), 2005-10, Vol.129 (4), p.1198-1209

2005

Volltextzugriff (PDF)

Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production

Journal of hepatology, 2014-11, Vol.61 (5), p.984-993

2014

Volltextzugriff (PDF)

Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Hepatology international, 2021-12, Vol.15 (6), p.1421-1430

2021

Volltextzugriff (PDF)

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients

Frontiers in immunology, 2017-05, Vol.8, p.621-621

2017

Volltextzugriff (PDF)

Hepatocellular carcinoma‐associated single‐nucleotide variants and deletions identified by the use of genome‐wide high‐throughput analysis of hepatitis B virus

The Journal of pathology, 2017-10, Vol.243 (2), p.176-192

2017

Volltextzugriff (PDF)

The Impact of Type 2 Diabetes on the Development of Hepatocellular Carcinoma in Different Viral Hepatitis Statuses

Cancer epidemiology, biomarkers & prevention, 2009-07, Vol.18 (7), p.2054-2060

2009

Volltextzugriff (PDF)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients

Viruses, 2022-08, Vol.14 (8), p.1812

2022

Volltextzugriff (PDF)

Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Hepatology international, 2024-06, Vol.18 (3), p.1066-1066

2024

Volltextzugriff (PDF)

1 – 25 von 310

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SeriePlos One

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(281)
Mit Volltextzugriff
(270)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(227)
Life Sciences & Biomedicine
(186)
Humans
(166)
Male
(126)
Female
(115)
Middle Aged
(105)
Adult
(96)
Gastroenterology & Hepatology
(81)
Biological And Medical Sciences
(76)
Aged
(73)
Medical Sciences
(73)
Infectious Diseases
(58)
Hepatitis B Virus
(49)
Viral Diseases
(46)
Human Viral Diseases
(45)
Viral Hepatitis
(44)
Antiviral Agents - Therapeutic Use
(41)
Hepatitis B, Chronic - Drug Therapy
(40)
Hepatitis B Virus - Genetics
(39)
Hepatitis B
(36)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(174)
Ingenta
(151)
EZB Electronic Journals Library
(144)
Journals@Ovid
(122)
Elsevier ScienceDirect Journals Complete
(77)
Wiley-Blackwell Journals
(68)
NUS Single-Journal Subscriptions
(68)
Wiley Online Library
(60)
IngentaConnect Journals
(55)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(45)
Springer journals
(18)
IEEE Xplore
(15)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(12)
Oxford Journals
(12)
Oxford Journals 2020 Medicine
(12)
Nature Journals
(11)
JSTOR
(7)
BMJ Publishing
(4)
Taylor & Francis Journals
(4)
PAIS Index
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

Agalactosyl IgG induces liver fibrogenesis via Fc gamma receptor 3a on human hepatic stellate cells

Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

Urine DNA biomarkers for hepatocellular carcinoma screening

Vortex Ring Formation Following Shock Wave Diffraction in Low-Pressure Environments

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

Drug‐induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

Novel urine cell-free DNA methylation markers for hepatocellular carcinoma

Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations

Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV

All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production

Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients

Hepatocellular carcinoma‐associated single‐nucleotide variants and deletions identified by the use of genome‐wide high‐throughput analysis of hepatitis B virus

The Impact of Type 2 Diabetes on the Development of Hepatocellular Carcinoma in Different Viral Hepatitis Statuses

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients

Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Aktive Filter

Suchergebnisse filtern